Edgewise Therapeutics, Inc. (EWTX) Stock Ticker
EWTX right now
Market factors today
Unlock the full EWTX picture
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
EWTX stock facts
| Ticker symbol | EWTX |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $4.2B |
| CEO | Kevin Koch |
| Employees | 127 |
| Headquarters | Boulder, CO, US |
| IPO date | 2021-03-26 |
| Website | www.edgewisetx.com |
What you can see for EWTX on Tickr
Live EWTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the EWTX report.
Rankings
FAQ
What is the ticker symbol for Edgewise Therapeutics, Inc.?
The ticker symbol for Edgewise Therapeutics, Inc. is EWTX, listed on the NASDAQ Global Select.
What is EWTX?
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully…